AQILION AB, legacy PULS (Partners for Development Investments in Life Sciences, P.U.L.S. AB), was founded on February 1, 2002, in Helsingborg, Sweden, by a group of people with backgrounds in the pharmaceutical industry and research.

The founders had realized that many commercially interesting projects never leave the academic setting due to lack of resources and inadequate product and business development skills. They also noted a growing need in the pharma industry to license new projects and products. Thus, the company began as a bridge between academia and industry.

The company became operational in the fall of 2003. The first project, LIDDS AB, started in the fall of 2003, followed by DuoCort AB in the spring of 2004. Aqilion (legacy PULS) has altogether started 13 projects of which 11 have become separate companies.

In early 2019, PULS changed its name to Aqilion as a step toward repositioning the company and strengthening brand awareness.

Since year-end of 2019, Aqilion’s projects are Alhena (in-house project), Alnitak 1 and 2 (in-house projects), Laccure (affiliate project) and Oncorena (affiliate project).

Exited projects in brief

Two were floated on the Swedish stock market:
LIDDS in 2014 and AcuCort in 2017. Aqilion remains the principal owner of AcuCort with a 25.9% stake (June 30, 2020).

Three were discontinued:
Pharmapnea in 2014, Adenovir Pharma in 2019 and Trophea in 2019.

Four were sold:
Ambria Technlogy in 2009, DuoCort Pharma in 2011, Belina in 2019 and Glactone Pharma in 2019.